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Abstract 
Hepatic fibrosis and its end-stage sequelae of cirrhosis and liver cancer are major causes of morbidity and mortality 
throughout the world and their prevalence is rising, largely due to the increasing impact of chronic viral hepatitis and non-
alcoholic steatohepatitis (NASH). Therapies currently available are only to manage patients suffering from or progressing to liver 
cirrhosis. In Western medicine the lack of treatments to target the arrest or reverse the progression of disease hampered the 
clinicians to successfully treat these patients with established cirrhosis. This review focused on the Hepatic fibrosis and 
importance herbal medicines for prevention and treatment of chronic liver diseases. 
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1. Introduction 
The use of medicinal plants for treatment of various diseases has been practiced for centuries in the Asian 
continent. It is thought that indigenous medical practice of Sri Lanka was introduced from India long ago. However, 
historical evidence indicates that a traditional system of veterinary medicine existed even 5 000 years ago during the 
time of King Rawana. The Indian ayurvedic system came to Sri Lanka, especially with the advent of Buddhism 
around 2600 years ago, where a group of "Ayurvedic" specialists accompanied "MahindaThero" when he came to 
"Mihintale". On the other hand, Siddha system of medicine came to Sri Lanka with the Hindu Tamil migrants and 
Uani system came with the Muslim merchants who came to Sri Lanka. Thus, indigenous medical practices of Sri 
Lanka became a mixture of all these systems, but still the traditional system of medicine is being practiced1.Thepress 
practice of indigenous medicine in Sri Lanka was reaching the peak during 337 to 365 A. D. at the time of king 
"Buddadasa"2. However, with the invasion of the western power the practice of indigenous medicine was gradually 
declined but is still being practiced in isolated pockets in remote areas of the country  
In the monographs of indigenous medical practices valuable information on diagnosis, rationales of the treatment 
with prognosis are described for various diseases, including respiratory, uro–genital, nervous, musculoskeletal, 
gastro-intestinal disorders as well as external disease conditions such as wounds, broken bones/horns, skin diseases3. 
According to the indigenous medical practice, a part or whole of a single plant or mixture of various parts of plants 
including flowers, rhizomes, stems, fruits, roots, tubers, leaves, stem-barks, seeds are used to make various herbal 
preparations including decoctions, juices, powders, oil extracts. The unique feature in indigenous veterinary 
medicine is that, for the same disorder the type and part of plants and their proportions used can be vary with the 
locality/region or with the practitioner3–5. The herbal recipes are usually combined with tattooing and do inchantation 
(a formula of prayer addressed to a deity or devil).  
 
2. Hepatic Fibrosis and Historical Perspective 
    Hepatic fibrosis and its end-stage sequelae of cirrhosis and liver cancer are major causes of morbidity and 
mortality throughout the world and their prevalence is rising, largely due to the increasing impact of chronic viral 
hepatitis and non-alcoholic steatohepatitis (NASH). It is hoped better disease prevention and more effective antiviral 
therapies will help reduce this disease burden. However, there remains a major need both to understand the 
mechanisms involved in hepatic fibrosis in order to design treatments that prevent liver scarring, and to develop 
better therapies for the treatment of cirrhosis and its complications. 
    Liver fibrosis results from chronic damage to the liver in conjunction with the accumulation of extra cellular 
matrix (ECM) proteins, which is a characteristic of most types of chronic liver diseases6. The main causes of liver 
fibrosis include chronic HCV infection, alcohol abuse, and nonalcoholic steatohepatitis (NASH). The accumulation 
of ECM proteins distorts the hepatic architecture by forming a fibrous scar, and the subsequent development of 
nodules of regenerating hepatocytes defines cirrhosis. Cirrhosis produces hepatocellular dysfunction and increased 
intrahepatic resistance to blood flow, which result in hepatic insufficiency and portal hypertension, respectively7. 
Hepatic fibrosis was historically thought to be a passive and irreversible process due to the collapse of the hepatic 
parenchyma and its substitution with a collagen-rich tissue8.  
 Currently, it is considered a model of the wound-healing response to chronic liver injury. Early clinical reports in 
the 1970s suggested that advanced liver fibrosis is potentially reversible9. However, liver fibrosis received little 
attention until the 1980s, when hepatic stellate cells (HSCs), formerly known as lipocytes, Ito cells, or perisinusoidal 
cells, were identified as the main collagen-producing cells in the liver10. This cell type undergoes a dramatic 
phenotypic activation in chronic liver diseases with the acquisition of fibrogenic properties11. Methods to obtain 
HSCs from both rodent and human livers were rapidly standardized in the 1980s12 and prolonged culture of HSCs on 
plastic was widely accepted as a model for the study of activated HSCs and the key signals that modulate HSCs’ 
fibrogenic actions were delineated13. Experimental models for studying liver fibrogenesis in rats and in transgenic 
mice were developed, which corroborated the cell culture studies and led to the identification of key fibrogenic 
mediators14.  
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At the clinical level, the natural history of liver fibrosis, from early changes to liver cirrhosis, was delineated in 
patients with chronic HCV infection15. Rapid and slower fibrosers were identified, and genetic and environmental 
factors influencing fibrosis progression were partially uncovered. Since the demonstration, in the 1990s, that even 
advanced liver fibrosis is reversible,researchers have been stimulated to identify antifibrotic therapies16. 
Biotechnology and pharmaceutical companies are increasingly interested in developing antifibrotic programs, and 
clinical trials are currently underway. However, the most effective therapy for treating hepatic fibrosis to date is still 
to remove the causative agent17. 
 A number of drugs are able to reduce the accumulation of scar tissue in experimental models of chronic liver 
injury. Recently, NASH has been recognized as a major cause of liver fibrosis18. First described by Ludwig et al. it is 
considered part of the spectrum of nonalcoholic fatty liver disease19. These range from steatosis to cirrhosis and can 
eventually lead to hepatocellular carcinoma. NASH is a component of the metabolic syndrome, which is 
characterized by obesity, type II diabetes mellitus, and dyslipidemia, with insulin resistance as a common feature. As 
the prevalence of obesity is rapidly increasing, a rise in the prevalence of NASH is anticipated. Three systems that 
have been attracted much attention in liver fibrosis and portal hypertension to date includesendothelin system, 
sympathetic adrenergic system and the renin angiotensin system (RAS). However, the RAS blockers and agonists 
have been shown to be the most promising drugs, and the testing of these compounds in human liver diseases await 
the data generated from experimental animal models20. 
 
3. The Rennin Angiotensin System and Hepatic Fibrosis   
 
Authors’ group has played a leading role in establishing that angiotensin (Ang) II, a key effector peptide of the 
renin angiotensin system (RAS), plays a central role in the pathogenesis of hepatic fibrosis and its complications20–22. 
This work has stimulated major interest in the potential therapeutic role of RAS blockade in liver disease. In addition 
to establishing the central role of Ang II, authorshave shown that there is an alternate, angiotensin converting 
enzyme 2 (ACE2) dependent arm of the RAS which is activated in both experimental and human chronic liver 
disease and opposes many of the vasoconstrictive and profibrotic effects of Ang II and may contribute to 
vasodilatation in cirrhosis23–25.  
The demonstration that stellate cells, key effectors of hepatic fibrosis, contract, proliferate, and produce 
profibrotic cytokines and collagen I in response to Ang II suggested that this peptide stimulates fibrogenesis via its 
direct effect on these cells17,26. Studies using RAS inhibitors showed that the RAS plays a major role in the 
pathogenesis of hepatic fibrosis21. These findings are now supported by a range of subsequent studies which have 
shown that angiotensin converting enzyme (ACE) inhibitors and Ang II type 1 receptor (AT1) blockers attenuate 
liver fibrosis and down-regulate key inflammatory and profibrotic cytokines20.  
 
4. The ACE2/Ang-(1-7)/Mas Axis in Chronic Liver Disease 
 
The classical view of the RAS is of a linear cascade in which ACE is a key enzyme, converting Ang I to the 
potent vasoconstrictor and profibrotic cytokine Ang II, which acts via the AT1 receptor. It is now known that there is 
alternate arm of the RAS in which ACE2, a homologue of ACE, degrades Ang II and generates Ang-(1-7), which in 
contrast to Ang II, has vasodilatory, anti-growth and anti-proliferative actions25,27,28. These effects are mediated in 
part by the Mas receptor, a G protein-coupled receptor (GPCR). This ACE2/Ang-(1-7)/Mas axis is thought to 
intrinsically regulate the RAS system by reducing Ang II levels and producing Ang-(1-7), thus counterbalancing the 
potentially harmful effects of Ang II (Figure 1). Infusion of Ang-(1-7) into cirrhotic rats ameliorates fibrosis induced 
by bile duct ligation26,29.  
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5. Herbal Treatments for Liver Fibrosis  
 
    Herbal medicines have been used in the treatment of liver diseases for a long time  in different part of the world 
including China30–36, India37 Iran38, Japan39,40 Mexico41, Sri Lanka3–5 and several other countries. Diagnosis and 
treatment of liver fibrosis with integrative Chinese Medicine is well established. Several reports have demonstrated 
a prophylactic and therapeutic role of Chinese Medicine herbal formulas on liver fibrosis. “BJ-JN” is a traditional 
Chinese formulation and has an anti-oxidant activity and inhibitory activity on the activation of hepatic stellate cells 
(HSCs) in rats with hepatic fibrosis induced by CCl4, and a significant reduction in the proliferation of HSCs in 
vitro, leading to a significant reduction in collagen secretion30. 
 The regulation of  ‘redox’ state within the tissue by “Yinchenhao Decoction” and “Huangqi Decoction” has been 
suggested as a potential mechanism by which they counter hepatic fibrosis in rats32. Thus, whilst “Yinchenhao 
Decoction” is responsible for elimination of hepatic lipid peroxide levels, “Huangqi Decoction” appears to enhance 
anti-oxidative ability of the tissue32. Moreover, “Yi Guan Jian” acts against heptocyte apoptosis and HSC activation, 
resulting in a diminished hepatic fibrosis36. The “TCM 319” is also a Chinese Medicine formula consisting f six 
Chinese herb extracts attenuated hepatic fibrosis induced by CCl4 in rats35. The anti-fibrotic effect of TCM 319 
recipe has been shown to be associated with down–regulation of gene expression of tissue inhibitor of matrix 
metalloproteinase 1 (TIMP-1), platelet derived growth factor (PDGF-B) and PDGF-Rbeta, which were accompanied 
by reduced protein expression of PDGF-Rbeta and transforming growth factor-beta 1 (TGF-beta1)35.  
 Treatment with “BushenRougan Recipe” (BSRGR), another traditional Chinese herbal medicine, decreases the 
expression of collagen type I and connective tissue growth factor (CTGF) mRNAs in rats with hepatic fibrosis33. 
(Furthermore, “Dan-shao-hua-xian” capsules, preparations of traditional Chinese medicine enhance the expression 
of PPAR-gamma but decrease that of TNF-alpha and NF-kappaB in the fibrotic liver of rats induced by CCl4 
adminsitration31. Furthermore “Danshensu”, “Baicalin”, “Astragalus” and “Panaxnotoginsengsaponins (PNS)” four 
other Chinese herb products have been shown to ameliorate hepatic fibrosis in rats by mechanisms that exert 
inhibitory action on activation and proliferation of HSCs, and on the expression of type I and type III collagen by 
HSCs34. Collectively, these findings suggest that Chinese herbal preparations can block the progression of hepatic 
fibrosis and have both prophylactic and therapeutic potential in the treatment of cirrhosis. 
    The protective effect of “Liv-52” an Iranian herbal preparation on liver cirrhosis has been reported38. These 
protective effects were associated with anti-inflammatory, anti-oxidative and immunomodulating properties of the 
components in the herbal preparation38. It has also been reported that methanol extract of aerial parts of 
Leucophyllum frutescensa, a Mexican plant, is hepatoprotective41. The observations by Chinese, Iranian and 
Mexican investigators are supported by a Japanese study in which a traditional Japanese medicines “Hochu-ekki-to” 
and “Ninjin-youei-to” have been demonstrated to be effective as anti-fibrotic agents, and may exert their action by 
Fig. 1. The two arms of the RAS. The system has two main effector peptides, angiotensin II and angiotensin-(1-7), which act through different 
receptors, AT1 and Mas, respectively. Angiotensin-(1-7) is primarily produced from angiotensin II via ACE2. The net effect of RAS 
activation reflects a balance between the relative activity of ACE and ACE2. 
274   Missaka Priyadarsana Bandara Wijayagunawardane et al. /  Procedia Chemistry  14 ( 2015 )  270 – 276 
inhibiting pro-fibrotic cytokine production, resulting in the suppression of collagen synthesis and secretion into 
extracellular matric in the liver39. In support of these findings there are several indigenous Sri Lankan herbal 
preparations that are available for the treatment of end stage cirrhosis3–5. Few such recipes are given in Appendix A. 
 Drugs currently available are only to manage patients suffering from liver cirrhosis and its complications such as 
variceal bleeding associated with portal hypertension. In Western medicine the lack of treatments to target the arrest 
or reverse the progression of disease hampered the clinicians to successfully treat these patients with established 
cirrhosis. At present, the use of herbal medicines for prevention and treatment of chronic liver diseases is in the 
focus of attention for both the physicians and the patients; the reasons for such shift towards the use of herbals 
include a considerable cost of conventional drugs, adverse drug reactions, and their inefficacy38. A successfully 
treated case of severe acute hepatitis with severe liver dysfunction in a 45-year-old well-nourished, healthy man with 
“Inchinko”, a Chinese herbal medicine has been described and its hepatoprotective and choleretic effects were 
identified40. These therapies include several stages of treatment depending on the condition of the patient3–5. 
Therefore, extensive research should be carried out to investigate the therapeutic efficacy of indigenous herbal 
recipes in progressive liver fibrosis. 
 
6. Conclusions 
 
    Identification of the active ingredients of herbal recipes will help to develop therapeutic strategies to arrest the 
progression of liver injury into liver cirrhosis. A reduction in fibrosis will be expected to improve portal 
hypertension, a life threatening complication of cirrhosis and thus, they can be efficiently utilized to reduce the death 
rate due to the end-stage liver cirrhosis and portal hypertension. 
 
Acknowledgements 
 
    Authors wish to acknowledge Alexander von Humboldt Foundation, Germany and National research Council of 
Sri Lanka for financial support. 
 
 
Appendix A. Some herbal recipes available for complete cure of liver disease in indigenous Sri 
Lankamedicine 
 
A.1. Recipe 1 
 
The rhizome of Zingiber officinale, the seeds of Coriandrum sativum,the fruit of Solanum virginianum the roots of 
Solanum melongina, the heartwood of Polyalthia longifolia: 11g each, add 0.8 L of water boiled down to 0.1 L on 
slow fire. Use after adding Rock salt and the seed powder of Piper longum. 
 
A.2. Recipe 2 
 
The fruits of Terminalia chebula and Phyllanthu semblica, the seeds of Piper longum and Coriandrum sativum, 
and Rock salt equal amounts, roast and grind. Boil infusion of below ingredients: the rhizome of Zingiber 
officinale, the seeds of Coriandrum sativum, the fruit of Solanum virginianum; equal amounts of each ingredient. 
Mix and add some sugar. 
 
A.3. Recipe 3 
 
The rhizome of Zingiber officinale, the seeds of Piper longum, Piper nigrum, Coriandrum sativum, Nigella sativa, 
Cuminum cyminum, Brassica juncea, Elettaria cardamomum, the bark of  Cinnamomum verum, Kokoona 
zeylanica, the leaves of Cinamomum tamala, Picrorhiza kurrooa, the aril and kernel of Myristica fragrans, the 
immature nut of Syzygium aromaticum, the flowers of Messua ferrea, Carbon, Rock salt, impure Sodium chloride, 
Black salt,  Yawakaralunu; take equal amounts, roast, grind and give with warm water. 
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A.4. Recipe 4 
 
The seeds of Holarrhena antidysenterica, Macrotyloma uniflorum, the cotyledons of Caesalpinia bonduc, 
Lagenandra lancifolia, the fruits of Terminalia chebula, the gum of Ferula assafoetida, the rhizome of Acorus 
calamus, the roots of Aristolochia indica, the seeds of Macrotyloma uniflorum, Rock salt; Take equal amounts. 
Roast, grind and dissolve powder in hot water. Add the fruit juice of Citrus auantifolia and gingerly oil.  
 
A.5. Recipe 5 
 
The rhizome of Zingiber officinale, Cucuma longa, the seeds of Piper nigrum, Piper longum, Elettaria 
cardamomum, Coriandrum sativum, Cuminum cyminum, Nigella sativa and Brassica juncea, the bark of Kokoona 
zeylanica, the tubers of Languas galanga; equal amounts, roast, grind and add to warm water. 
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